Early Diagnosis of Invasive Lung Aspergillosis

Launched by UNIVERSITY HOSPITAL OSTRAVA · May 5, 2023

Keywords

ClinConnect Summary

**Summary of the Clinical Trial on Early Diagnosis of Invasive Lung Aspergillosis**

This clinical trial is focused on improving the early diagnosis of a serious lung infection known as invasive pulmonary aspergillosis (IPA), which can occur in critically ill patients, especially those with weakened immune systems. The study aims to test new methods for detecting IPA using advanced techniques that identify specific substances related to the infection. By doing so, the researchers hope to provide a clearer diagnosis faster, which could lead to timely treatment and better survival chances for patients suffering from this condition.

To participate in the study, patients typically need to be critically ill with symptoms like rapid breathing, low oxygen levels, and other signs of severe infection. Some key criteria for joining the trial include having a high respiratory rate, confusion, or signs of kidney issues. Participants will undergo tests to help confirm the presence of IPA more accurately and quickly than current methods allow. This trial is currently recruiting patients, and those who take part can expect to contribute to important research that could improve the way doctors diagnose and treat this life-threatening infection.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • respiratory rate ≥ 30 breaths/min
• • PaO2/FiO2 ratio ≤ 250
• • multilobar infiltrates
• • confusion/disorientation
• • uremia (blood urea nitrogen level ≥ 20mg/dL)
• • leucocytosis (white blood cell count \> 12000/mL) or
• • leukopenia (white blood cell count \< 4 x 109/L)
• • thrombocytopenia (platelet count \< 100 x 109/L)
• • hyperthermia (core temperature \> 38 °C)
• • hypothermia (core temperature \< 36 °C)
• • hypotension requiring aggressive fluid resuscitation
• • invasive mechanical ventilation and septic shock requiring vasopressors
• • Bronchoalveolar Lavage Fluid (BALF) and/or Endotracheal Aspirate (ETA)
• Exclusion Criteria:
• • - patients, in whom PTX3, Aspergillus qPCR, and HPLC-FTICR were not performed or were performed after the start of antifungal treatment